Top

Published in:

01-01-2019 | Short Communication

Identification of a novel GREM1 duplication in a patient with multiple colon polyps

Published in: Familial Cancer | Issue 1/2019

Abstract

Hereditary mixed polyposis syndrome (HMPS) is a hereditary syndrome that is characterized by multiple colon polyps of mixed pathologic subtypes and an increased risk for colorectal cancer. A 40 kb duplication in the 5′ regulatory region of the GREM1 gene was recently found to be the causal mutation in a subset of Ashkenazi Jewish families with HMPS. Given this discovery, the GREM1 5′ regulatory region is now analyzed on many different multi-gene cancer panels, however the data on duplications distinct from the 40 kb duplication remains minimal. Herein we report a novel 24 kb tandem duplication of the 5′ regulatory region of GREM1 in a patient without Ashkenazi Jewish heritage, who had a family history that was concerning for Lynch syndrome and satisfied Amsterdam II criteria. This is only the third reported GREM1 duplication separate from the 40 kb Ashkenazi Jewish duplication, and is the only reported duplication to selectively involve exon 1 of GREM1. This finding supports comprehensive testing of the GREM1 regulatory region in families of all ethnicities with multiple colon polyps or colon cancer, and when Lynch syndrome is suspected.

Jaeger EE, Woodford-Richens KL, Lockett M et al (2003) An ancestral Ashkenazi haplotype at the HMPS/CRAC1 locus on 15q13-q14 is associated with hereditary mixed polyposis syndrome. Am J Hum Genet 72(5):1261–1267. https://doi.org/10.1086/375144 CrossRefPubMedPubMedCentral

Whitelaw SC, Murday VA, Tomlinson IP et al (1997) Clinical and molecular features of the hereditary mixed polyposis syndrome. Gastroenterology 112(2):327–334CrossRefPubMed

Jaeger E, Leedham S, Lewis A et al (2012) Hereditary mixed polyposis syndrome is caused by a 40-kb upstream duplication that leads to increased and ectopic expression of the BMP antagonist GREM1. Nat Genet 44(6):699–703. https://doi.org/10.1038/ng.2263 CrossRefPubMedPubMedCentral

Rohlin A, Eiengard F, Lundstam U et al (2016) GREM1 and POLE variants in hereditary colorectal cancer syndromes. Genes Chromosomes Cancer 55(1):95–106. https://doi.org/10.1002/gcc.22314 CrossRefPubMed

Venkatachalam R, Verwiel ET, Kamping EJ et al (2011) Identification of candidate predisposing copy number variants in familial and early-onset colorectal cancer patients. Int J Cancer 129(7):1635–1642. https://doi.org/10.1002/ijc.25821 CrossRefPubMed

Davis H, Irshad S, Bansal M et al (2015) Aberrant epithelial GREM1 expression initiates colonic tumorigenesis from cells outside the stem cell niche. Nat Med 21(1):62–70. https://doi.org/10.1038/nm.3750 CrossRefPubMed

Batts LE, Polk DB, Dubois RN, Kulessa H (2006) Bmp signaling is required for intestinal growth and morphogenesis. Dev Dyn 235(6):1563–1570. https://doi.org/10.1002/dvdy.20741 CrossRefPubMed

National Comprehensive Cancer Network (2017) Genetic/familial high-risk assessment: colorectal (version 2.2017). National Comprehensive Cancer Network, Fort Washington

Sopik V, Phelan C, Cybulski C, Narod SA (2015) BRCA1 and BRCA2 mutations and the risk for colorectal cancer. Clin Genet 87(5):411–418. https://doi.org/10.1111/cge.12497 CrossRefPubMed

10.

National Comprehensive Cancer Network (2017) Genetic/familial high-risk assessment: breast and ovarian (version 2.2017). National Comprehensive Cancer Network, Fort Washington

11.

Lieberman S, Walsh T, Schechter M et al (2017) Features of patients with hereditary mixed polyposis syndrome caused by duplication of GREM1 and implications for screening and surveillance. Gastroenterology 152(8):1876–1880.e1. https://doi.org/10.1053/j.gastro.2017.02.014 CrossRefPubMed

12.

Ziai J, Matloff E, Choi J, Kombo N, Materin M, Bale AE (2016) Defining the polyposis/colorectal cancer phenotype associated with the Ashkenazi GREM1 duplication: counselling and management recommendations. Genet Res 98:e5. https://doi.org/10.1017/S0016672316000021 CrossRef

13.

Lindor NM, Rabe K, Petersen GM et al (2005) Lower cancer incidence in Amsterdam-I criteria families without mismatch repair deficiency: familial colorectal cancer type X. JAMA 293(16):1979–1985. https://doi.org/10.1001/jama.293.16.1979 CrossRefPubMedPubMedCentral

Title: Identification of a novel GREM1 duplication in a patient with multiple colon polyps
Publication date: 01-01-2019
Published in: Familial Cancer / Issue 1/2019
Print ISSN: 1389-9600
Electronic ISSN: 1573-7292
DOI: https://doi.org/10.1007/s10689-018-0090-6

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2019

Delineating a new feature of constitutional mismatch repair deficiency (CMMRD) syndrome: breast cancer

Hemangioblastoma in Hereditary Leiomyomatosis and Renal Cell Cancer Syndrome: a phenotypic overlap between VHL and HLRCC Syndromes

Sarcoma in neurofibromatosis 2: case report and review of the literature

Unsolicited information letters to increase awareness of Lynch syndrome and familial colorectal cancer: reactions and attitudes

Candidate susceptibility variants in angioimmunoblastic T-cell lymphoma

Germline CDH1 mutations are a significant contributor to the high frequency of early-onset diffuse gastric cancer cases in New Zealand Māori

Keynote webinar | Spotlight on antibody–drug conjugates in cancer